Novo Nordisk: A long acting, selective human insulin analog, NN1213, for weight management Novo Nordisk Stock Tumbles on CagriSema Trial Data. Why Investors Have Doubts. Barron's Novo Nordisk's next generation weight loss drug CagriSema matches Lilly's Zepbound in major trial, but doesn't surpass it CNN Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants Gabe 2024 Diabetes, Obesity and Metabolism Wiley Online Library Cagrilintide (AM833) Long acting amylin analog. Beta cells make TWO hormones: insulin and amylin. Amylin slows stomach emptying and reduces appetite. Cagrilintide is a long acting synthetic amylin designed for once weekly dosing THIRTEEN new Ozempic like drugs are coming in the next few years as part of weight loss goldrush Daily Mail Online